Gabapentin as Adjunctive Treatment for Postoperative Pain Control

Status Completed

Clinical Trial Summary

The specific aims of this research study are to use 600 mg gabapentin as an adjunctive treatment for acute postoperative pain control in order to reduce postoperative opiate consumption and improve postoperative pain control.

Clinical Trial Description

After consent has been obtained for the study and the cesarean has been completed, when the participant is in the recovery room, she will take the first pill of the study drug. This will occur approximately 30-60 minutes after the cesarean is completed. The time of first dose will be noted on the data capture form. The following will then occur:

- Participants will take study capsules (either 600 mg gabapentin or placebo) every 8 hours for the first 48 hours after beginning the study. The nurse on the unit will be sent the study drug in a blinded capsule by the Investigational Pharmacy.

- Participants will be asked about postoperative pain on a Visual Analog Scale by the care nurses or study personnel before each dose of study drug, before receiving any opioid medication, 2-4 hours after study drugs are consumed, at 24, 36 and 48 hours post surgery, and any other times during routine postoperative clinical care would warrant. Women record pain postoperatively on a similar scale as part of routine clinical care. Prescription pain medication will be given per clinical routine care. Study personnel will note how many pills were sent home.

- One week (6-9 days) after the cesarean delivery, participants will be contacted by phone or other preferred method and asked about pain score, somnolence scores, dizziness, nausea, depression, any problems they are experiencing, and asked how many pain pills are left in their prescriptions given when they went home. These data will be recorded.

An Edinburgh Depression Scale will also be administered upon consent, at 48 hours, and again at one week after delivery. If the scores meet the specified criteria, the provider will by notified or if the subject has already been discharged from the hospital, she will be given contact information for follow up care. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02490345
Study type	Interventional
Source	Indiana University
Contact
Status	Completed
Phase	Phase 1
Start date	October 2015
Completion date	June 29, 2017

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06020391` - Cooperation for Better Treatment of Polypharmacy in the Community	N/A
Completed	`NCT01931683` - Dosing Study of Remifentanil for Smooth Removal of the Laryngeal Mask Airway (LMA)	Phase 4
Withdrawn	`NCT03938077` - A Community-University Approach to Preventing HIV	N/A
Completed	`NCT02973724` - EC95 of Remifentanil for Preventing Cough	N/A
Completed	`NCT01152970` - F.Y.I.: Flint Youth Injury Study	N/A
Completed	`NCT03330782` - Remifentanil for Preventing Propofol Injection Pain in Elderly Patients	Phase 4
Completed	`NCT01489683` - Intubating Conditions During Propofol-remifentanil Anesthesia With Topical Lidocaine	N/A
Completed	`NCT03368456` - Preventing HIV/STI in Urban Adolescents Via an mHealth Primary Care Intervention	N/A
Completed	`NCT02379455` - Cooperation for Improved Pharmacotherapy in Home-dwelling Elderly People Receiving Polypharmacy - The COOP Study	N/A
Completed	`NCT01852539` - Dexmedetomidine for Laryngeal Mask Airway Insertion	Phase 4
Completed	`NCT01963130` - Does Vildagliptin Affect Portal Vein Pressure In Patients With Type 2 Diabetes Mellitus? A Cross Sectional Study	N/A
Recruiting	`NCT01496105` - Efficacy Study of Topical Application of Lidacaine Spray Prior to IUD Insertion	Phase 4
Completed	`NCT02334046` - Remifentanil for Smooth Emergence in Elderly Patients	Phase 4
Completed	`NCT00876941` - Assessing Screening Plus Brief Intervention's Resulting Efficacy (ASPIRE) to Stop Drug Use	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.